News

AnaptysBio: Fully Valued -- With Major Litigation Uncertainty

SeekingAlpha·07:01ANAB▲+1.8%

Why This IPO Stock, An AnaptysBio Spinoff, Just Surged

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.

Yahoo·16:10ANAB▲+1.8%

AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story

AnaptysBio (ANAB) has drawn fresh attention after recent trading left the stock down about 18% over the past month and roughly 30% over the past 3 months. That slump now frames how investors assess its royalty driven biotech model. Short term momentum for AnaptysBio has clearly cooled, with the share price down 18.4% over 30 days and 30.4% over 3 months. However, the 1 year total shareholder return of 118.2% and 3 year total shareholder return above 2.7x show a very different longer term...

Yahoo·00:29ANAB▲+1.8%

AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise

AnaptysBio has delivered very strong gains over the past few years, which puts a spotlight on whether the current share price is properly supported by its earnings profile. After such a run, the key issue for you is whether the recent market enthusiasm lines up with what the business is actually earning today. Over the past 3 years the stock has climbed 273.3%, which now raises the question of how much of that rise is backed by sustainable earnings power. The business model relies heavily on...

Yahoo·19:17ANAB▲+1.8%

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.

Benzinga·10:04ANAB▲+1.8%

AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance

AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to US$6.06 for the quarter and US$6.09 for the six months. A key driver of the very large reported profit was a US$181.5 million income-tax benefit from releasing a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an...

Yahoo·10:11ANAB▲+1.8%

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit. The tax adjustment reflects greater expected use of tax assets following […]

Yahoo·23:38ANAB▲+1.8%

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.

Benzinga·06:30ANAB▲+1.8%

Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.

Benzinga·05:17ANAB▲+1.8%

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo·17:35ANAB▲+1.8%

Top movers in Monday's after hours session

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

ChartMill·17:00

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionLitigation with GSK and Tesaro: trial held

Yahoo·16:15

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose 8.44% to

Benzinga·13:06

AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34) per share from the

Benzinga·12:55ANAB▲+1.8%

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund’s Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As of June 30, 2026, the top ten positions comprised approximately 72% of the portfolio, and the portfolio held approximately […]

Yahoo·10:34ANAB▲+1.8%

AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup

AnaptysBio (ANAB) combines high growth momentum with strong technicals and a breakout setup. Learn about its ratings, metrics, and risks.

ChartMill·04:01ANAB▲+1.8%